Shopping Cart 0
Cart Subtotal
USD 0

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2018, provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.

Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 6, 51, 54, 1, 2, 58, 12 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 8, 7, 10 and 6 molecules, respectively.

Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL) (Oncology).

- The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 8

Chronic Lymphocytic Leukemia (CLL) - Overview 9

Chronic Lymphocytic Leukemia (CLL) - Therapeutics Development 10

Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 38

Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 52

Chronic Lymphocytic Leukemia (CLL) - Drug Profiles 99

Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 911

Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 925

Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 928

Appendix 943


List Of Figure

List of Figures

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018


List Of Table

List of Tables

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by ACEA Biosciences Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by ADC Therapeutics SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aeglea BioTherapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Altor BioScience Corp, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Amgen Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aptevo Therapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by ArQule Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Asana BioSciences LLC, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca Plc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Baliopharm AG, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bayer AG, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by BeiGene Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biogen Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bionomics Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biothera Pharmaceutical Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Co, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by CARsgen Therapeutics Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corp, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celldex Therapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellectar Biosciences Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celltrion Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by CrystalGenomics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Debiopharm International SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Deciphera Pharmaceuticals LLC, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Eli Lilly and Co, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Enlivex Therapeutics Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Eureka Therapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by GeneaMed Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genentech Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Grupo Ferrer Internacional SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Heidelberg Pharma AG, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hybrigenics SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Igenica Biotherapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immatics Biotechnologies GmbH, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corp, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Inflection Biosciences Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innovent Biologics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Invectys SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Iovance Biotherapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by JHL Biotech Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kancera AB, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kiromic Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kite Pharma Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ligand Pharmaceuticals Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Loxo Oncology Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by LSK BioPartners Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by MEI Pharma Inc, H1 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Chronic Lymphocytic Leukemia (CLL) Therapeutic Products under Development, Key Players in Chronic Lymphocytic Leukemia (CLL) Therapeutics, Chronic Lymphocytic Leukemia (CLL) Pipeline Overview, Chronic Lymphocytic Leukemia (CLL) Pipeline, Chronic Lymphocytic Leukemia (CLL) Pipeline Assessment


Companies

4SC AG

AbbVie Inc

ACEA Biosciences Inc

ADC Therapeutics SA

Aeglea BioTherapeutics Inc

Altor BioScience Corp

Amgen Inc

Aptevo Therapeutics Inc

ArQule Inc

Asana BioSciences LLC

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Baliopharm AG

Bayer AG

BeiGene Ltd

Bellicum Pharmaceuticals Inc

Biogen Inc

Bionomics Ltd

Biothera Pharmaceutical Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

CARsgen Therapeutics Ltd

Celgene Corp

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Celltrion Inc

Cellular Biomedicine Group Inc

CrystalGenomics Inc

Cyclacel Pharmaceuticals Inc

Debiopharm International SA

Deciphera Pharmaceuticals LLC

Eli Lilly and Co

Enlivex Therapeutics Ltd

Eureka Therapeutics Inc

F. Hoffmann-La Roche Ltd

GeneaMed Ltd

Genentech Inc

Gilead Sciences Inc

Grupo Ferrer Internacional SA

Heidelberg Pharma AG

Hutchison MediPharma Ltd

Hybrigenics SA

Igenica Biotherapeutics Inc

Immatics Biotechnologies GmbH

Immunomedics Inc

Incyte Corp

Inflection Biosciences Ltd

Innate Pharma SA

Innovent Biologics Inc

Invectys SA

Iovance Biotherapeutics Inc

JHL Biotech Inc

Juno Therapeutics Inc

Kancera AB

Karyopharm Therapeutics Inc

Kiromic Inc

Kite Pharma Inc

LFB SA

Ligand Pharmaceuticals Inc

Loxo Oncology Inc

LSK BioPartners Inc

Lymphocyte Activation Technologies SA

MEI Pharma Inc

MENTRIK Biotech LLC

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Miltenyi Biotec GmbH

Miragen Therapeutics Inc

MorphoSys AG

NantKwest Inc

Nichi-Iko Pharmaceutical Co Ltd

Nordic Nanovector ASA

Novartis AG

Oncternal Therapeutics Inc

Ono Pharmaceutical Co Ltd

PEP-Therapy SAS

Pfizer Inc

PIQUR Therapeutics AG

Plexxikon Inc

Qurient Co Ltd

Respiratorius AB

Rhizen Pharmaceuticals SA

Sandoz International GmbH

Sanofi

Selvita SA

Supratek Pharma Inc

Targazyme Inc

TCR2 Therapeutics Inc

TG Therapeutics Inc

Tolero Pharmaceuticals Inc

TRACON Pharmaceuticals Inc

Trillium Therapeutics Inc

TTY Biopharm Company Ltd

United BioPharma Inc

Verastem Inc

Viralytics Ltd

ZIOPHARM Oncology Inc

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2018, provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.

Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 6, 51, 54, 1, 2, 58, 12 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 8, 7, 10 and 6 molecules, respectively.

Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL) (Oncology).

- The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 8

Chronic Lymphocytic Leukemia (CLL) - Overview 9

Chronic Lymphocytic Leukemia (CLL) - Therapeutics Development 10

Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 38

Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 52

Chronic Lymphocytic Leukemia (CLL) - Drug Profiles 99

Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 911

Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 925

Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 928

Appendix 943


List Of Figure

List of Figures

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018


List Of Table

List of Tables

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by ACEA Biosciences Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by ADC Therapeutics SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aeglea BioTherapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Altor BioScience Corp, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Amgen Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aptevo Therapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by ArQule Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Asana BioSciences LLC, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca Plc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Baliopharm AG, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bayer AG, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by BeiGene Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biogen Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bionomics Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biothera Pharmaceutical Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Co, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by CARsgen Therapeutics Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corp, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celldex Therapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellectar Biosciences Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celltrion Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by CrystalGenomics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Debiopharm International SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Deciphera Pharmaceuticals LLC, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Eli Lilly and Co, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Enlivex Therapeutics Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Eureka Therapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by GeneaMed Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genentech Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Grupo Ferrer Internacional SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Heidelberg Pharma AG, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hybrigenics SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Igenica Biotherapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immatics Biotechnologies GmbH, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corp, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Inflection Biosciences Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innovent Biologics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Invectys SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Iovance Biotherapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by JHL Biotech Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kancera AB, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kiromic Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kite Pharma Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ligand Pharmaceuticals Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Loxo Oncology Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by LSK BioPartners Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by MEI Pharma Inc, H1 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Chronic Lymphocytic Leukemia (CLL) Therapeutic Products under Development, Key Players in Chronic Lymphocytic Leukemia (CLL) Therapeutics, Chronic Lymphocytic Leukemia (CLL) Pipeline Overview, Chronic Lymphocytic Leukemia (CLL) Pipeline, Chronic Lymphocytic Leukemia (CLL) Pipeline Assessment


Companies

4SC AG

AbbVie Inc

ACEA Biosciences Inc

ADC Therapeutics SA

Aeglea BioTherapeutics Inc

Altor BioScience Corp

Amgen Inc

Aptevo Therapeutics Inc

ArQule Inc

Asana BioSciences LLC

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Baliopharm AG

Bayer AG

BeiGene Ltd

Bellicum Pharmaceuticals Inc

Biogen Inc

Bionomics Ltd

Biothera Pharmaceutical Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

CARsgen Therapeutics Ltd

Celgene Corp

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Celltrion Inc

Cellular Biomedicine Group Inc

CrystalGenomics Inc

Cyclacel Pharmaceuticals Inc

Debiopharm International SA

Deciphera Pharmaceuticals LLC

Eli Lilly and Co

Enlivex Therapeutics Ltd

Eureka Therapeutics Inc

F. Hoffmann-La Roche Ltd

GeneaMed Ltd

Genentech Inc

Gilead Sciences Inc

Grupo Ferrer Internacional SA

Heidelberg Pharma AG

Hutchison MediPharma Ltd

Hybrigenics SA

Igenica Biotherapeutics Inc

Immatics Biotechnologies GmbH

Immunomedics Inc

Incyte Corp

Inflection Biosciences Ltd

Innate Pharma SA

Innovent Biologics Inc

Invectys SA

Iovance Biotherapeutics Inc

JHL Biotech Inc

Juno Therapeutics Inc

Kancera AB

Karyopharm Therapeutics Inc

Kiromic Inc

Kite Pharma Inc

LFB SA

Ligand Pharmaceuticals Inc

Loxo Oncology Inc

LSK BioPartners Inc

Lymphocyte Activation Technologies SA

MEI Pharma Inc

MENTRIK Biotech LLC

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Miltenyi Biotec GmbH

Miragen Therapeutics Inc

MorphoSys AG

NantKwest Inc

Nichi-Iko Pharmaceutical Co Ltd

Nordic Nanovector ASA

Novartis AG

Oncternal Therapeutics Inc

Ono Pharmaceutical Co Ltd

PEP-Therapy SAS

Pfizer Inc

PIQUR Therapeutics AG

Plexxikon Inc

Qurient Co Ltd

Respiratorius AB

Rhizen Pharmaceuticals SA

Sandoz International GmbH

Sanofi

Selvita SA

Supratek Pharma Inc

Targazyme Inc

TCR2 Therapeutics Inc

TG Therapeutics Inc

Tolero Pharmaceuticals Inc

TRACON Pharmaceuticals Inc

Trillium Therapeutics Inc

TTY Biopharm Company Ltd

United BioPharma Inc

Verastem Inc

Viralytics Ltd

ZIOPHARM Oncology Inc